Trial reportPsychopharmacology2014
A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression.
Trial report in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 7 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Efficacy and safety of electroacupuncture in patients with postpartum depression: a meta-analysis.Frontiers in psychiatry · 2024Pooled it
- Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of Antidepressants: A Systematic Review and Meta-analysis.JAMA psychiatry · 2022Pooled it
- Comparative efficacy and acceptability of pharmacotherapies for postpartum depression: A systematic review and network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Brexanolone in Postpartum Depression:Journal of women's health (2002) · 2021Pooled it
- Antidepressant treatment for postnatal depression.The Cochrane database of systematic reviews · 2021Pooled it
- Treatment of depression, anxiety, and trauma-related disorders during the perinatal period: A systematic review.Clinical psychology review · 2018Pooled it
- Antidepressant treatment for postnatal depression.The Cochrane database of systematic reviews · 2014Pooled it
- Exercise in Pregnancy and Risk of Postpartum Depression: A Randomised Controlled Trial.BJOG : an international journal of obstetrics and gynaecology · 2026Trial
- Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study.Archives of women's mental health · 2020Trial
- Comparative Efficacy of Interventions for the Prevention and Treatment of Postpartum Depression: A Bayesian Network Meta-analysis.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Review
- Postpartum Depression and the Emerging Mother-Infant Relationship: Associations With Selective Serotonin Reuptake Inhibitor Medication Use.JAACAP open · 2026Article
- Supplementary approaches to perinatal depression: a review of pathogenesis, herbal interventions, and dietary supplements.Frontiers in psychology · 2025Review
- The pathophysiology of estrogen in perinatal depression: conceptual update.Archives of women's mental health · 2024Review
- Understanding and Addressing Male Postpartum Depression: Incidence, Causes, Diagnosis, and Management Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Use of electroconvulsive therapy during postpartum: A retrospective chart review.Indian journal of psychiatry · 2024Article
- Consensus Panel Recommendations for the Pharmacological Management of Breastfeeding Women with Postpartum Depression.International journal of environmental research and public health · 2024Review
- Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS).Archives of women's mental health · 2024Article
- Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA.Neuroscience and biobehavioral reviews · 2023Review
- Fecal microbiota as a predictor of acupuncture responses in patients with postpartum depressive disorder.Frontiers in cellular and infection microbiology · 2023Article
- Development of neuroactive steroids for the treatment of postpartum depression.Journal of neuroendocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
rationalePostpartum depression (PMD) occurs in roughly 10 % of postpartum women and negatively impacts the mother and her offspring, but there are few placebo-controlled studies of antidepressant treatment in this population.
objectiveThe objective was this study is to compare the selective serotonin reuptake inhibitor (SSRI) sertraline to placebo for treating PMD.
methodsThis was a single-center, 6-week, randomized double-blind placebo-controlled trial of sertraline with a 1-week placebo lead-in. The participants (n = 38) were women with depression onset within 3 months of delivery; a subset (n = 27) met strict DSM-IV criteria for PMD (onset within 4 weeks of delivery). The participants were prescribed sertraline 50 mg or placebo daily to a maximum of 200 mg/day. Primary outcome variables were the Hamilton Depression Rating Scale (HAM-D) and Clinical Global Impressions (CGI) scores, which were used to determine the rates of response and remission.
resultsSertraline produced a significantly greater response rate (59 %) than placebo (26 %) and a more than twofold increased remission rate (53 % vs. 21 %). Mixed models did not reveal significant group by time effects, although in the subset of women who met the DSM-IV criteria, there was a statistically significant group by time effect for the HAM-D, Hamilton Anxiety Rating Scale (HAM-A), and CGI.
conclusionsWomen with PMD are more likely to have a remission of their depression with sertraline treatment, a finding that is more pronounced in women who have onset of depression within 4 weeks of childbirth. These data support the continued use of 4 weeks for the DSM-5 postpartum onset specifier for major depressive disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.